Sandoz is to acquire worldwide rights to the Mycamine (micafungin) antifungal brand from Astellas, in a deal that will see the Novartis subsidiary make an upfront payment of up to $75m as well as potential milestones.
Describing Mycamine – known as Funguard in Japan – as a “leading global echinocandin, one of three major antifungal classes,” Sandoz said the acquisition would “significantly reinforce Sandoz’s hospital offering and leading anti-infectives portfolio” while also supporting the firm’s efforts to combat
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?